Surface modification of lipid-based nanocarriers for cancer cell-specific drug targeting

2017 ◽  
Vol 47 (3) ◽  
pp. 203-227 ◽  
Author(s):  
Chang Hyun Kim ◽  
Sang Gon Lee ◽  
Myung Joo Kang ◽  
Sangkil Lee ◽  
Young Wook Choi
Keyword(s):  
Surface Modification ◽  
Cancer Cell ◽  
Drug Targeting ◽  
Specific Drug

PROSTATE CANCER CELL-SPECIFIC DRUG TARGETING USING NOVEL NANOPARTICLES

2008 ◽  
Vol 179 (4S) ◽  
pp. 230-230
Author(s):  
Rajesh Singh ◽  
Shailesh Singh ◽  
James W Lillard
Keyword(s):  
Prostate Cancer ◽  
Cancer Cell ◽  
Drug Targeting ◽  
Prostate Cancer Cell ◽  
Specific Drug

Novel Strategies of Third Level (Organelle-specific) Drug Targeting: An Innovative Approach of Modern Therapeutics

2020 ◽  
pp. 102315
Author(s):  
Amjad Ali Khan ◽  
Khaled S. Allemailem ◽  
Ahmad Almatroudi ◽  
Saleh A. Almatroodi ◽  
Mohammed A. Alsahli ◽  
...  
Keyword(s):  
Drug Targeting ◽  
Innovative Approach ◽  
Specific Drug

Surface modification with cholesteryl acetyl carnitine, a novel cationic agent, elevates cancer cell uptake of the PEGylated liposomes

2021 ◽  
Vol 609 ◽  
pp. 121148
Author(s):  
Fahimeh Zahednezhad ◽  
Javid Shahbazi Mojarrad ◽  
Parvin Zakeri-Milani ◽  
Behzad Baradaran ◽  
Mohammad Mahmoudian ◽  
...  
Keyword(s):  
Surface Modification ◽  
Cancer Cell ◽  
Cell Uptake ◽  
Pegylated Liposomes

scholarly journals Antigen-specific drug-targeting used to manipulate an immune response in vivo.

1987 ◽  
Vol 84 (20) ◽  
pp. 7232-7236 ◽  
Author(s):  
M. M. Abu-hadid ◽  
R. B. Bankert ◽  
G. L. Mayers
Keyword(s):  
Immune Response ◽  
Drug Targeting ◽  
Specific Drug

scholarly journals Longitudinal Transcriptional Response of Glycosylation-Related Genes, Regulators, and Targets in Cancer Cell Lines Treated With 11 Antitumor Agents

2017 ◽  
Vol 16 ◽  
pp. 117693511774725 ◽  
Author(s):  
Julia Krushkal ◽  
Yingdong Zhao ◽  
Curtis Hose ◽  
Anne Monks ◽  
James H Doroshow ◽  
...  
Keyword(s):  
Cell Lines ◽  
Cancer Cell ◽  
Drug Targeting ◽  
Time Course ◽  
Antitumor Agents ◽  
Transcriptional Response ◽  
Cancer Cell Lines ◽  
Expression Data ◽  
Cancer Pathways ◽  
Genes Encoding

Cellular glycosylation processes are vital to cell functioning. In malignant cells, they are profoundly altered. We used time-course gene expression data from the NCI-60 cancer cell lines treated with 11 antitumor agents to analyze expression changes of genes involved in glycosylation pathways, genes encoding glycosylation targets or regulators, and members of cancer pathways affected by glycosylation. We also identified glycosylation genes for which pretreatment expression levels or changes after treatment were correlated with drug sensitivity. Their products are involved in N-glycosylation and O-glycosylation, fucosylation, biosynthesis of poly- N-acetyllactosamine, removal of misfolded proteins, binding to hyaluronic acid and other glycans, and cell adhesion. Tumor cell sensitivity to multiple agents was correlated with transcriptional response of C1GALT1C1, FUCA1, SDC1, MUC1; members of the MGAT, GALNT, B4GALT, B3GNT, MAN, and EDEM families; and other genes. These genes may be considered as potential candidates for drug targeting in combination therapy to enhance treatment response.

Rational design of urea-based glutamate carboxypeptidase II (GCPII) inhibitors as versatile tools for specific drug targeting and delivery

2014 ◽  
Vol 22 (15) ◽  
pp. 4099-4108 ◽  
Author(s):  
Jan Tykvart ◽  
Jiří Schimer ◽  
Jitka Bařinková ◽  
Petr Pachl ◽  
Lenka Poštová-Slavětínská ◽  
...  
Keyword(s):  
Drug Targeting ◽  
Rational Design ◽  
Specific Drug ◽  
Glutamate Carboxypeptidase Ii ◽  
Glutamate Carboxypeptidase

Site-Specific Drug Carriers

1986 ◽  
Vol 15 (4) ◽  
pp. 197-202 ◽  
Author(s):  
E Tomlinson
Keyword(s):  
Drug Targeting ◽  
Drug Carriers ◽  
The Body ◽  
Specific Drug ◽  
Carrier System ◽  
Site Specific ◽  
Drug Molecules ◽  
Do So

Site-specific drug carriers are required to exclusively deliver drug molecules to difficult targets within the body. They should do so in a form which protects the drug and host from one another. This contribution reviews the reasons for drug targeting, and describes some of the features required of two types of carrier system, i.e., particulates and soluble (bio)conjugates.

Sign in / Sign up

Export Citation Format

Share Document